gp130 cytokine family and bone cells

Cytokine

Volumn 12, Issue 10, 2000, Pages 1455-1468

  Heymann, Dominique ^a,b   Rousselle, Anne Valérie ^a  

^a Universite de Nantes   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Bone; Cardiotrophin 1; Ciliary neurotrophic factor; Gp130; IL 11; IL 6; Leukaemia inhibitory factor; Oncostatin M; Osteoblast; Osteoclast

Indexed keywords

CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M;

ANIMAL CELL; BONE CELL; BONE METABOLISM; BONE REMODELING; CELL DIFFERENTIATION; GIANT CELL TUMOR; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PAGET BONE DISEASE; PRIORITY JOURNAL; RAT; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0033790375     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2000.0747     Document Type: Review

References (212)

1. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption
2. Cellular biology of bone-resorbing cells
3. How the osteoclast degrades bone
4. Bone
5. Osteoclast function is activated by osteoblastic cells through mechanism involving cell-to-cell contact
6. Integrins
7. Skeletal tissue response to cytokines
8. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity
9. Cytokines, growth factors and osteoclasts
10. Molecular cloning and expression of an IL-6 signal transducer, gp 130
11. The leukemia inhibitory factor and its receptor
12. Cardiotrophin-1: A multifunctional cytokine that signals via LIF receptor-gp130 dependent pathways
13. Neurotrophin and ciliary neurotrophic factor: Their biology
14. Are LIF and related cytokines functionally equivalent?
15. Interleukin-6
16. Interleukin-11
17. Interleukin 11: An overview
18. The biology of interleukin 11
19. Interleukin-11 and its receptor
20. Localization of the human oncostatin M gene (OSM) to chromosome 22q12, distal to the Ewing's sarcoma breakpoint
21. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes
22. Oncostatin M binds the high affinity leukemia inhibitory factor receptor
23. High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. Molecular and cellular distribution
24. Leukemia inhibitory factor (LIF) and oncostatin M (OSM) high affinity binding require additional receptor subunits besides GP130 and GP190
25. Biochemical characterization and purification of HILDA, a human lymphokine active on eosinophils and bone marrow cells
26. Production of human interleukin for DA cells (HILDA)/leukemia inhibitory factor (LIF) activated monocytes
27. LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells
28. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-α and TGF-β
29. Expression of leukemia inhibitory factor is regulated in human mesenchymal cells
30. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor
31. Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): Regulation of its production and possible roles in bone metabolism
32. Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells
33. Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA
34. Constitutive production of human interleukin for DA cells/leukemia inhibitory factor by human tumor cell lines derived from various tissues
35. Molecular cloning, sequence analysis and functional expression of a novel growth regulator: Oncostatin M
36. Purification and characterization of cytostatic lymphocytes produced by activated human T-lymphocytes: Synergistic antiproliferative activity of transforming growth factor-β1, interferon γ and oncostatin M for human melanoma cells
37. Oncostatin M production and regulation by human polymorphonuclear neutrophils
38. A myelosclerotic syndrome in mice engrafted with cells producing high levels of leukemia inhibitory factor (LIF)
39. Fatal syndrome in mice engrafted with cells producing high levels of leukemia inhibitory factor
40. Osteoblasts display receptors for and responses to leukemia-inhibitory factor
41. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells
42. Leukemia inhibitory factor (LIF): A growth factor with pleiotropic effects on bone biology
43. Presence of leukemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution
44. Culturing of cells from giant cell tumour of bone on natural and synthetic calcified substrata: The effect of leukemia inhibitory factor and vitamin D3 on the resorbing activity of osteoclast-like cells
45. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
46. Oncostatin-M: A new bone active cytokine that activates osteoblasts and inhibits bone resorption
47. Interleukin-6-type cytokine signalling through the gp130/Jak pathway
48. Activation of the JAK-STAT signal transduction pathway by oncostatin-M in cultured human and mouse osteoblastic cells
49. Activation of the janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation
50. Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts
51. The LIF/IL-6 subfamily of cytokines induce protein phosphorylation and signal transduction by nonreceptor tyrosine kinases in human and murine osteoblasts
52. Leukemia inhibitory factor: A novel bone-active cytokine
53. Leukemia inhibitory factor binds with high affinity to preosteoblastic RCT-1 cells and potentiates the retinoic acid induction of alkaline phosphatase
54. The effect of leukemia inhibitory factor on bone in vivo
55. Osteoblast programmed cell death (appptosis): Modulation by growth factors and cytokines
56. Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3-E1) cells
57. Effects of leukemia inhibitory factor on bone resorption and DNA synthesis in neonatal mouse calvaria
58. Regulation of osteoblast proliferation by leukemia inhibitory factor
59. Leukemia inhibitory factor is mitogenic to osteoblasts
60. Leukemia inhibitory factor inhibits osteogenic differentiation in rat calvaria cell cultures
61. LIF, but not IL-6, regulates osteoprogenitor differentiation in rat calvaria cell cultures: Modulation by dexamethasone
62. Recombinant human leukemia inhibitory factor is mitogenic for human bone-derived osteoblast-like cells
63. Heterotopic implantation of mouse bone-marrow cells. An in vivo model allowing analysis of mineral phases during mineralization processes
64. The effect of leukemia inhibitory factor (LIF) on hematopoietic and stromal precursor cells in murine long-term bone marrow culture
65. Leukemia inhibitory factor and oncostatin M influence the mineral phases formed in a murine heterotopic calcification model: A fourier transform-infrared microspectroscopic study
66. Effects of leukemia inhibitory factor and oncostatin M on bone mineral formed in in vitro rat bone-marrow stromal cell culture: Physicochemical aspects
67. Leukemia inhibitory factor produces hypercalcemia in rats without altering bone histomorphometry of the tibia
68. Osteoclastic resorption of calcium phosphate ceramics with different hydroxyapatite/β-tricalcium phosphate ratios
69. Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal bone mouse metacarpal bones in culture
70. Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone cultures
71. A differentiation-inducing factor produced by the osteoblastic cell line MC3T3-E1 stimulates bone resorption by promoting osteoclast formation
72. Upmodulation of multinucleated cell formation in long-term human bone marrow cultures by leukemia inhibitory factor (LIF)
73. Oncostatin M stimulates macrophage-polykaryon formation in long-term human bone marrow cultures
74. Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures
75. Ultrastructural study of degradation of calcium phosphate ceramic by human monocytes and modulation of this activity by HILDA/LIF cytokine
76. Increased osteoclastic differentiation by PMMA particle-associated macrophages. Inhibitory effect by interleukin 4 and leukemia inhibitory factor
77. Inhibition of bone resorption by selective inactivators of cysteine-proteases
78. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and identification of MMPs and TIMP-1 in isolated osteoclasts
79. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts
80. Cysteine protease production by human osteosarcoma cells (MG63, SaOS2) and its modulation by soluble factors
81. Induction of metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3
82. Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic node morphologies
83. Developmental abnormalities in mice transgenic for bovine oncostatin M
84. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation
85. Blastocyst implantation depends on maternal expression of leukemia inhibitory factor
86. Osteoclasts are present in gp130-deficient mice
87. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death
88. GP 130 and the interleukin-6 family of cytokines
89. Interleukin-11: Review of molecular, cell biology, and clinical use
90. Interleukin-6
91. The biological effects of interleukin 6
92. PCR phenotyping of cytokines, growth factors and their receptors and bone matrix proteins in human osteoblast-like cell lines
93. Osteoclasts are not the major source of interleukin-6 in mouse parietal bone
94. Interleukin-13 inhibits cell proliferation and stimulates interleukin-6 formation in isolated human osteoblasts
95. Retinoic acid suppresses interleukin-6 synthesis induced by prostaglandins in osteoblasts
96. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells
97. Sphingosine modulates interleukin-6 synthesis in osteoblasts
98. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens
99. 17beta-estradiol antagonizes effects of lalpha, 25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures
100. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro
101. I1-6 produced by osteoblasts and induces bone resorption
102. Regulation of NFIL-6 and IL-6 expression by basic fibroblast growth factor in osteoblasts
103. Microgravity induces prostaglandin E2 and interleukin-6 production in normal rat osteoblasts: Role in bone demineralization
104. Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic cytokine
105. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production
106. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors
107. The role of gp130-mediated signals in osteoclast development: Regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures
108. Involvement of different second messengers in parathyroid hormone- and interleukin-1-induced interleukin-6 and interleukin-11 production in human bone marrow stomal cells
109. Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells
110. Inhibition of interleukin-11 by interferon-α in human bone marrow stromal cells
111. Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein
112. Human osteoblast-like cells do not respond to interleukin-6
113. Lack of autocrine effects of IL-6 on human bone marrow stromal osteoprogenitor cells
114. Effects of interleukin-6 in cellular function in UMR-106-01 osteoblast-like cells
115. Transcriptional activation of the p21 (WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effect on human osteoblastic cells
116. Interleukin-6-type cytokines stimulates mesenchymal progenitor differentiation toward the osteoblastic lineage
117. Interleukin-6 inhibits bone formation in vitro
118. IL-6 stimulates osteoclast-like multincleated cell formation in long term human marrow cultures by inducing IL-1 release
119. I1-6 mediates the effects of IL-1 or TNF, but not PTHrp or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures
120. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption
121. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo
122. Interleukin-6 does not mediate the stimulation by prostaglandin E2, parathyroid hormone, or 1, 25 dihydroxyvitamin D3 of osteoclast differentiation and bone resorption in neonatal mouse parietal bones
123. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo
124. The effect of interleukin-6 and soluble interleukin-6 receptor protein on the bone resorptive activity of human osteoclasts generated in vitro
125. The effect of hemopoietic growth factors on the generation of osteoclast-like cells in mouse bone marrow cultures
126. + hematopoietic bone marrow cells in vitro
127. Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors
128. Effects of interleukin-6 secreted by engineered human stromal cells on osteoclasts in human bone
129. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone
130. Production of interleukin-6 by human osteoclast-like cells from giant cell tumor of bone
131. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors
132. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation
133. 2+ sensing in the regulation of osteoclastic bone resorption
134. Increased osteoclast development after estrogen loss: Mediation by interleukin-6
135. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
136. Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women
137. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement
138. Effects of recombinant human interleukin-6 administration on bone in rhesus monkeys
139. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice
140. Estrogen's bone protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells
141. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptors
142. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow
143. Effect of monoclonal anti-human gp130 antibody (GPX7) on bone turnover in normal and ovariectomized rats
144. Interleukin-11: A new cytokine critical for osteoclast development
145. The cellular actions of interleukin-11 on bone resorption in vitro
146. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors
147. Recombinant human interleukin-11 does not modify biochemical parameters of bone remodeling and bone mineral density in adult ovariectomized rats
148. Regulation of matrixmetalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption
149. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow
150. IgG1 plasmacytosis in interleukin 6 transgenic mice
151. Generation of plasmacytomas with the chromosomal translocation (12; 15) in interleukin 6 transgenic mice
152. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, branchial remodelling, and airways obstruction
153. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis
154. Increased levels of leukemia inhibitory factor (LIF) in urine and tissue culture supernatant from human primary bone tumours
155. Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: An immunohistochemical study
156. Cytokines expressed in multinucleated cells: Paget's disease and giant cell tumors versus normal bone
157. Morphology of bone metastasis
158. Cytokines in bone: Local translators in cell-to-cell communications
159. Interleukin 6: A potential autocrine/paracrine factor in Paget's disease of bone
160. IL-6 is produced by osteoblasts and induces bone resorption
161. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis
162. Production and regulation of interleukin-11 by breast cancer cells
163. The mouse mammary tumor cell line, MMT060562, produces prostaglandin E2 and leukemia inhibitory factor and supports osteoclast formation in vitro via a stromal dependent pathway
164. Bone resorption induced by a metastatic human melanoma cell line
165. Modulation of LIF expression in human melanoma cells by oncostatin M
166. The critical role of interleukin-6, interleukin-1β and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma
167. Mechanisms of bone lesions in multiple myeloma
168. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp 130
169. Ciliary neurotrophic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer GP130
170. Interleukin-family of cytokine and gp130
171. Evidence that interleukin 6 produced by osteoclasts enhances myeloma cell growth in vivo
172. Mechanisms of bone lesions in multiple myeloma and lymphoma
173. Role of bone marrow stromal cells in the growth of human multiple myeloma
174. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
175. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
176. Serum oncostatin M in multiple myeloma: Association with prognostic factors
177. C-reactive protein and β2microglobulin produce a simple and powerful myeloma staging system
178. Bone histomorphometry in Paget's disease
179. Interleukin-6, IL-6 receptor and I1-6 nuclear factor gene expression in Paget's disease
180. Serum levels of interleukin-1 beta, tumor necrosis factor alpha and inteleukin-2 in rheumatoid arthritis. Correlation with disease activity
181. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis
182. Tumour necrosis factor stimulates resorption and inhibit synthesis of proteoglycan in cartilage
183. Interleukin-1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint
184. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: Evidence for synergistic interactions between cytokines in vivo
185. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory athritides
186. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis
187. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis
188. In situ hybridization of IL-6 in rheumatoid arthritis
189. The synovial expression and serum levels of interleukin-6, interlukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis
190. Antagonism of the IL-6 cytokine subfamily - A potential strategy for more effective therapy in rheumatoid arthritis
191. Leukemia inhibitory factor stimulates proteoglycan resorption in porcine articular cartilage
192. Oncostatin M stimulates resorption and inhibits synthesis of proteoglycan in pig cartilage explants
193. Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints
194. Oncostatin M induces leukocytes infiltration and cartilage proteoglycan degradation in vivo in goat joints
195. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis
196. Induction of cytokine expression by leukemia inhibitory factor
197. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes
198. Effects of exogenous IL-1β, TNF-α, IL-6, IL-8 and LIF on cytokine production by human chondrocytes
199. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
200. Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblasts
201. Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases
202. Stimulation of TIMP-1 production by oncostatin M in human articular cartilage
203. Oncostatin-M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metallopproteinase-1 production by human synovial fibroblasts in vitro
204. Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes via de novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms
205. Role of oncostatin M in the regulation of cartilage macromolecule metabolism: Comment on the article by Nemoto et al
206. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis
207. A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis
208. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis
209. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
210. Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukemia inhibitory factor and oncostatin M
211. Recent advances toward understanding osteoclast physiology